Discovery and validation of novel protein markers in mucosa of portal hypertensive gastropathy

Abstract Background Portal hypertension induced esophageal and gastric variceal bleeding is the main cause of death among patients of decompensated liver cirrhosis. Therefore, a standardized, biomarker-based test, to make an early-stage non-invasive risk assessment of portal hypertension, is highly...

Full description

Bibliographic Details
Main Authors: Ying Zhu, Wen Xu, Wei Hu, Fang Wang, Yan Zhou, Jianguo Xu, Wei Gong
Format: Article
Language:English
Published: BMC 2021-05-01
Series:BMC Gastroenterology
Subjects:
Online Access:https://doi.org/10.1186/s12876-021-01787-5
id doaj-fea2961a79a34cda82cbcc74bf8fccf8
record_format Article
spelling doaj-fea2961a79a34cda82cbcc74bf8fccf82021-05-11T14:51:55ZengBMCBMC Gastroenterology1471-230X2021-05-0121111410.1186/s12876-021-01787-5Discovery and validation of novel protein markers in mucosa of portal hypertensive gastropathyYing Zhu0Wen Xu1Wei Hu2Fang Wang3Yan Zhou4Jianguo Xu5Wei Gong6Department of Gastroenterology, Shenzhen Hospital of Southern Medical UniversityDepartment of Gastroenterology, Shenzhen Hospital of Southern Medical UniversityDepartment of Gastroenterology, Shenzhen Hospital of Southern Medical UniversityDepartment of Gastroenterology, Shenzhen Hospital of Southern Medical UniversityInformation Management Section, Bethune International Peace HospitalDepartment of Liver Disease Center, Shenzhen Hospital of Southern Medical UniversityDepartment of Gastroenterology, Shenzhen Hospital of Southern Medical UniversityAbstract Background Portal hypertension induced esophageal and gastric variceal bleeding is the main cause of death among patients of decompensated liver cirrhosis. Therefore, a standardized, biomarker-based test, to make an early-stage non-invasive risk assessment of portal hypertension, is highly desirable. However, no fit-for-purpose biomarkers have yet been identified. Methods We conducted a pilot study consisting of 5 portal hypertensive gastropathy (PHG) patients and 5 normal controls, sampling the gastric mucosa of normal controls and PHG patients before and after endoscopic cyanoacrylate injection, using label-free quantitative (LFQ) mass spectrometry, to identify potential biomarker candidates in gastric mucosa from PHG patients and normal controls. Then we further used parallel reaction monitoring (PRM) to verify the abundance of the targeted protein. Results LFQ analyses identified 423 significantly differentially expressed proteins. 17 proteins that significantly elevated in the gastric mucosa of PHG patients were further validated using PRM. Conclusions This is the first application of an LFQ-PRM workflow to identify and validate PHG–specific biomarkers in patient gastric mucosa samples. Our findings lay the foundation for comprehending the molecular mechanisms of PHG pathogenesis, and provide potential applications for useful biomarkers in early diagnosis and treatment. Trial registration and ethics approval: Trial registration was completed (ChiCTR2000029840) on February 25, 2020. Ethics Approvals were completed on July 17, 2017 (NYSZYYEC20180003) and February 15, 2020 (NYSZYYEC20200005).https://doi.org/10.1186/s12876-021-01787-5BiomarkerLabel-free quantitative mass spectrometryLiver cirrhosisParallel reaction monitoringPortal hypertension gastropathyProteomics
collection DOAJ
language English
format Article
sources DOAJ
author Ying Zhu
Wen Xu
Wei Hu
Fang Wang
Yan Zhou
Jianguo Xu
Wei Gong
spellingShingle Ying Zhu
Wen Xu
Wei Hu
Fang Wang
Yan Zhou
Jianguo Xu
Wei Gong
Discovery and validation of novel protein markers in mucosa of portal hypertensive gastropathy
BMC Gastroenterology
Biomarker
Label-free quantitative mass spectrometry
Liver cirrhosis
Parallel reaction monitoring
Portal hypertension gastropathy
Proteomics
author_facet Ying Zhu
Wen Xu
Wei Hu
Fang Wang
Yan Zhou
Jianguo Xu
Wei Gong
author_sort Ying Zhu
title Discovery and validation of novel protein markers in mucosa of portal hypertensive gastropathy
title_short Discovery and validation of novel protein markers in mucosa of portal hypertensive gastropathy
title_full Discovery and validation of novel protein markers in mucosa of portal hypertensive gastropathy
title_fullStr Discovery and validation of novel protein markers in mucosa of portal hypertensive gastropathy
title_full_unstemmed Discovery and validation of novel protein markers in mucosa of portal hypertensive gastropathy
title_sort discovery and validation of novel protein markers in mucosa of portal hypertensive gastropathy
publisher BMC
series BMC Gastroenterology
issn 1471-230X
publishDate 2021-05-01
description Abstract Background Portal hypertension induced esophageal and gastric variceal bleeding is the main cause of death among patients of decompensated liver cirrhosis. Therefore, a standardized, biomarker-based test, to make an early-stage non-invasive risk assessment of portal hypertension, is highly desirable. However, no fit-for-purpose biomarkers have yet been identified. Methods We conducted a pilot study consisting of 5 portal hypertensive gastropathy (PHG) patients and 5 normal controls, sampling the gastric mucosa of normal controls and PHG patients before and after endoscopic cyanoacrylate injection, using label-free quantitative (LFQ) mass spectrometry, to identify potential biomarker candidates in gastric mucosa from PHG patients and normal controls. Then we further used parallel reaction monitoring (PRM) to verify the abundance of the targeted protein. Results LFQ analyses identified 423 significantly differentially expressed proteins. 17 proteins that significantly elevated in the gastric mucosa of PHG patients were further validated using PRM. Conclusions This is the first application of an LFQ-PRM workflow to identify and validate PHG–specific biomarkers in patient gastric mucosa samples. Our findings lay the foundation for comprehending the molecular mechanisms of PHG pathogenesis, and provide potential applications for useful biomarkers in early diagnosis and treatment. Trial registration and ethics approval: Trial registration was completed (ChiCTR2000029840) on February 25, 2020. Ethics Approvals were completed on July 17, 2017 (NYSZYYEC20180003) and February 15, 2020 (NYSZYYEC20200005).
topic Biomarker
Label-free quantitative mass spectrometry
Liver cirrhosis
Parallel reaction monitoring
Portal hypertension gastropathy
Proteomics
url https://doi.org/10.1186/s12876-021-01787-5
work_keys_str_mv AT yingzhu discoveryandvalidationofnovelproteinmarkersinmucosaofportalhypertensivegastropathy
AT wenxu discoveryandvalidationofnovelproteinmarkersinmucosaofportalhypertensivegastropathy
AT weihu discoveryandvalidationofnovelproteinmarkersinmucosaofportalhypertensivegastropathy
AT fangwang discoveryandvalidationofnovelproteinmarkersinmucosaofportalhypertensivegastropathy
AT yanzhou discoveryandvalidationofnovelproteinmarkersinmucosaofportalhypertensivegastropathy
AT jianguoxu discoveryandvalidationofnovelproteinmarkersinmucosaofportalhypertensivegastropathy
AT weigong discoveryandvalidationofnovelproteinmarkersinmucosaofportalhypertensivegastropathy
_version_ 1721443950870396928